Capital Expenditures - Cartesian Therapeutics Inc (NASDAQ:RNAC) - Alpha Spread

Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 16.54 USD 5.82% Market Closed
Market Cap: 353.6m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Cartesian Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cartesian Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Cartesian Therapeutics Inc
NASDAQ:RNAC
Capital Expenditures
-$2.3m
CAGR 3-Years
-26%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$858m
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$572m
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$965m
CAGR 3-Years
-14%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$481.8m
CAGR 3-Years
-12%
CAGR 5-Years
-47%
CAGR 10-Years
-23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$886.1m
CAGR 3-Years
-15%
CAGR 5-Years
-20%
CAGR 10-Years
-14%

See Also

What is Cartesian Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-2.3m USD

Based on the financial report for Jun 30, 2024, Cartesian Therapeutics Inc's Capital Expenditures amounts to -2.3m USD.

What is Cartesian Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-39%

Over the last year, the Capital Expenditures growth was -186%. The average annual Capital Expenditures growth rates for Cartesian Therapeutics Inc have been -26% over the past three years , -39% over the past five years .

Back to Top